EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Baseline Characteristics of Participants in STAREE: A Randomized Trial for Primary Prevention of Cardiovascular Disease Events and Prolongation of Disability‐Free Survival in Older People

Baseline-Merkmale der Teilnehmenden in STAREE: eine randomisierte Studie zur Primärprävention kardiovaskulärer Ereignisse und zur Verlängerung des behinderungsfreien Überlebens bei älteren Menschen

Sophia Zoungas iD, Chris Moran iD, Andrea J Curtis, Simone Spark, Zachary Flanagan, Lawrence Beilin iD, Trevor T-J Chong iD, Geoffrey C Cloud iD, Ingrid Hopper, Alissia Kost iD, John J McNeil iD, Stephen J Nicholls und 9 weitere

Journal of the American Heart Association · 19.11.2024 · 13 (22)

DOI: 10.1161/jaha.124.036357 ↗

Auf einen Blick

STAREE beschrieb die Ausgangsmerkmale von 9.971 älteren Menschen in einer randomisierten, doppelblinden, placebokontrollierten Studie mit Atorvastatin 40 mg. Die Kohorte war im Mittel 74,7 Jahre alt.

Fragestellung

Beschreibung der Baseline-Merkmale der Teilnehmenden in der STAREE-Studie zur Primärprävention kardiovaskulärer Ereignisse und zum behinderungsfreien Überleben.

Methode

Randomisierte, doppelblinde, placebokontrollierte Studie bei in der Gemeinde lebenden älteren Menschen in Australien; Baseline-Daten von Juli 2015 bis März 2023 erhoben und mit früheren Statin-Studien verglichen.

Ergebnisse

9.971 Teilnehmende; mittleres Alter 74,7±4,5 Jahre, 40 % ≥75 Jahre, 52 % Frauen. LDL-Cholesterin im Mittel 3,27 mmol/L (126 mg/dL), Hypertonie bei 43 %, mittlerer Blutdruck 136/80 mm Hg.

Schlussfolgerung der Autor:innen

STAREE ist die größte Primärpräventionsstudie mit Statinen und soll wichtige klinische Endpunkte zu majoren kardiovaskulären Ereignissen, behinderungsfreiem Überleben und Kognition bei älteren Menschen beantworten.

Kernaussagen

  • 9.971 Teilnehmende aus 1.583 Hausarztpraxen in Australien
  • 40 % waren ≥75 Jahre, 52 % waren Frauen
  • Mittleres LDL-Cholesterin: 3,27 mmol/L (126 mg/dL)

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 19.11.2024. Verfasst von Sophia Zoungas und 20 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Primary Prevention. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The risk–benefit balance of statin use in healthy older people is uncertain. We describe the baseline characteristics of the STAREE (Statins in Reducing Events in the Elderly) trial, which is a randomized, double‐blind, placebo‐controlled trial among community‐dwelling older people; the trial evaluated the effect of atorvastatin 40 mg for the prevention of major cardiovascular events (cardiovascular death, nonfatal myocardial infarction or stroke), and on disability‐free survival (survival free of both dementia and persistent physical disability). Methods and Results STAREE enrolled people aged ≥70 years from 1583 general practices across Australia with no history of clinical cardiovascular disease, diabetes, or dementia. Baseline data collected included demographic, clinical, cognitive (Modified Mini‐Mental State Examination), psychological (Center for Epidemiologic Studies Short Depression Scale), lifestyle, medical, physical, blood and urine measures, and quality of life. Demographic and clinical characteristics of study participants were then compared with publicly available landmark statin trials. A total of 9971 participants were recruited (mean±SD age 74.7±4.5 years, 4023 (40%) ≥75 years, 52% women) between July 2015 and March 2023. The mean low‐density lipoprotein cholesterol was 3.27 mmol/L (SD=0.72; 126 mg/dL). Hypertension was reported by 43% of participants and the mean blood pressure was 136/80 mm Hg. Compared with previous landmark statin trials that included primary prevention cohorts, STAREE is unique in including such a large number of older (≥75 years) independent‐living people.

Conclusions

STAREE is the largest primary prevention trial of statins powered to address the important clinical outcomes of major cardiovascular events, disability‐free survival, and cognition in older people. Registration https://www.clinicaltrials.gov ; Unique identifier: NCT02099123.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesHydroxymethylglutaryl-CoA Reductase InhibitorsPrimary PreventionHumansAgedFemaleMaleDouble-Blind MethodAustraliaAged, 80 and overAtorvastatinIndependent LivingTime FactorsAge FactorsTreatment OutcomeRisk Assessment

Stichwörter der Autor:innen

primary preventionrandomized clinical trialstatins

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsAtorvastatin

Autor:innen und Institutionen

  • School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia.
  • Aged Care Services Alfred Health Melbourne Victoria Australia.
  • Monash University Clinical Trials Centre, Faculty of Medicine Nursing and Health Sciences Monash University Melbourne Victoria Australia.
  • School of Medicine Royal Perth Hospital, University of Western Australia Perth Western Australia Australia.
  • Turner Institute for Brain and Mental Health, School of Psychological Sciences Monash University Melbourne Victoria Australia.
  • Department of Neurology Alfred Health Melbourne Victoria Australia.

ORCID-Profile: Sophia Zoungas, Chris Moran, Lawrence Beilin, Trevor T-J Chong, Geoffrey C Cloud, Alissia Kost, John J McNeil, Christopher M Reid, Joanne Ryan, Andrew M Tonkin, Anthony S Wierzbicki, Rory Wolfe, Zhen Zhou, Mark R Nelson

Zitieren

APA

Zoungas, S., Moran, C., Curtis, A. J., Spark, S., Flanagan, Z., Beilin, L., Chong, T. T., Cloud, G. C., Hopper, I., Kost, A., McNeil, J. J., Nicholls, S. J., Reid, C. M., Ryan, J., Tonkin, A. M., Ward, S., Wierzbicki, A. S., Wolfe, R., Zhou, Z., …, & STAREE investigator group (2024). Baseline Characteristics of Participants in STAREE: A Randomized Trial for Primary Prevention of Cardiovascular Disease Events and Prolongation of Disability‐Free Survival in Older People. Journal of the American Heart Association, 13(22). https://doi.org/10.1161/jaha.124.036357

Vancouver

Zoungas S, Moran C, Curtis AJ, Spark S, Flanagan Z, Beilin L, et al. Baseline Characteristics of Participants in STAREE: A Randomized Trial for Primary Prevention of Cardiovascular Disease Events and Prolongation of Disability‐Free Survival in Older People. Journal of the American Heart Association. 2024;13(22). doi:10.1161/jaha.124.036357

BibTeX
@article{Zoungas2024,
  author = {Zoungas, Sophia and Moran, Chris and Curtis, Andrea J and Spark, Simone and Flanagan, Zachary and Beilin, Lawrence and Chong, Trevor T-J and Cloud, Geoffrey C and Hopper, Ingrid and Kost, Alissia and McNeil, John J and Nicholls, Stephen J and Reid, Christopher M and Ryan, Joanne and Tonkin, Andrew M and Ward, Stephanie and Wierzbicki, Anthony S and Wolfe, Rory and Zhou, Zhen and Nelson, Mark R and STAREE investigator group, STAREE investigator group},
  title = {Baseline Characteristics of Participants in STAREE: A Randomized Trial for Primary Prevention of Cardiovascular Disease Events and Prolongation of Disability‐Free Survival in Older People},
  journal = {Journal of the American Heart Association},
  year = {2024},
  volume = {13},
  number = {22},
  doi = {10.1161/jaha.124.036357}
}
Kostenlos starten →